BRCA1 and ovarian carcinoma: Olaparib was recently approved for first-line maintenance treatment in BRCA1/2-mutated, newly diagnosed, advanced ovarian cancer after a complete response (CR)/partial response (PR) to platinum-based chemotherapy [340].